These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 15049234)

  • 1. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activated protein C--recent addition to therapy of sepsis].
    Gårdlund B; Sjölin J
    Lakartidningen; 2003 Jun; 100(26-27):2292-6. PubMed ID: 12872375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of activated protein C in the pathophysiology of severe sepsis.
    Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A
    Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 5. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 7. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 8. [Activated protein C in patients with septic shock: contra].
    Graf J
    Dtsch Med Wochenschr; 2010 Nov; 135(47):2371. PubMed ID: 21082531
    [No Abstract]   [Full Text] [Related]  

  • 9. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 10. Kigris. FDA approves first biologic for sepsis.
    Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924158
    [No Abstract]   [Full Text] [Related]  

  • 11. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 13. Activated protein C for sepsis.
    Toussaint S; Gerlach H
    N Engl J Med; 2009 Dec; 361(27):2646-52. PubMed ID: 20042756
    [No Abstract]   [Full Text] [Related]  

  • 14. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe sepsis: patient management focusing on administration of drotrecogin alpha (activated) infusion.
    Riddell C; Blackwood B
    Nurs Crit Care; 2006; 11(1):7-15. PubMed ID: 16471293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 17. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
    Kanji S; Perreault MM; Chant C; Williamson D; Burry L
    Intensive Care Med; 2007 Mar; 33(3):517-23. PubMed ID: 17325837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Rustige J
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698; author reply 1699-70. PubMed ID: 15273923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.